Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | DGKA | P23743 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | PAM | P19021 | 2/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11455382 | 1.00 | CYP1A2 (0.48) | CYP1A2ALDH1A1ALOX15TDP1TSHR | |
| SCHEMBL11260906 | 1.00 | CYP1A2 (0.48) | CYP1A2ALDH1A1ALOX15TDP1TSHR | |
| SCHEMBL49063 | 0.93 | CYP1A2 (0.52) | CYP1A2ALDH1A1ALOX15TDP1TSHR | |
| SCHEMBL11443788 | 0.86 | DGKA (0.55) | ALDH1A1TSHRDGKAPRSS1PRSS2 | |
| SCHEMBL48378 | 0.85 | CYP1A2 (0.45) | CYP1A2ALDH1A1ALOX15TDP1TSHR | |
| SCHEMBL10451645 | 0.85 | DGKA (0.58) | ALDH1A1TSHRDGKAPRSS1PRSS2 | |
| SCHEMBL11438853 | 0.85 | DGKA (0.58) | ALDH1A1TSHRDGKAPRSS1PRSS2 | |
| SCHEMBL1174146 | 0.84 | DGKA (0.46) | ALDH1A1TSHRDGKAPRSS1PRSS2 | |
| SCHEMBL11577455 | 0.84 | PRSS1 (0.51) | ALDH1A1TSHRDGKAPRSS1PRSS2 | |
| SCHEMBL10392177 | 0.84 | PRSS1 (0.51) | ALDH1A1TSHRDGKAPRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2020-05-21 | — | — | US | claimed |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-05-06 | — | — | US | claimed |
| US-20250188284-A1 | CAGING-GROUP-FREE PHOTOACTIVATABLE FLUORESCENT DYES AND THEIR USE | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E. V. (DE) | 2025-06-12 | — | — | US | disclosed |
| WO-2024211444-A2 | ANTIBIOTICS COMPRISING LPXH-TARGETING COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20240279174-A1 | ANTIBIOTICS COMPRISING LPXH-TARGETING COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2024-08-22 | — | — | US | disclosed |
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2023-12-05 | — | — | US | disclosed |
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-23 | — | — | US | disclosed |
| CN-111741948-B | Saturated ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | 日本烟草产业株式会社 | 2023-11-10 | — | — | CN | disclosed |
| EP-3760619-B1 | SATURATED RING-CONDENSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUND, AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2023-10-25 | — | — | EP | disclosed |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2002002520-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | disclosed |
| EP-1140967-A1 | TARGETED GENE TRANSFER USING G PROTEIN COUPLED RECEPTORS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-0979233-A4 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | PROLIGO L L C (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-2000039145-A1 | TARGETED GENE TRANSFER USING G PROTEIN COUPLED RECEPTORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2000-07-06 | — | — | WO | disclosed |
| EP-0979233-A1 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | NeXstar Pharmaceuticals, Inc. (US) | 2000-02-16 | — | — | EP | disclosed |
| US-5942387-A | Combinatorial process for preparing substituted thiophene libraries | ELI LILLY AND COMPANY (US) | 1999-08-24 | — | — | US | disclosed |
| WO-1998047910-A1 | METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | PROLIGO LLC (US) | 1998-10-29 | — | — | WO | disclosed |
| EP-0816309-A1 | Scavenger assisted combinatorial process for preparing libraries of urea and thiourea compounds | ELI LILLY AND COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
| US-5292741-A | Macrocycles incorporating quinazolinones | MERCK & CO., INC. (US) | 1994-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279174-A1 | ANTIBIOTICS COMPRISING LPXH-TARGETING COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | LPXN, PCSK9, RPN1 | CYP1A2 4535/4885ALDH1A1 4556/4885ALOX15 902/4885 |
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | RORC, RORB, RORA | CYP1A2 73/4885ALDH1A1 252/4885ALOX15 1887/4885 |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | CYP1A2 378/4885ALDH1A1 242/4885ALOX15 1354/4885 |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | CYP1A2 385/4885ALDH1A1 217/4885ALOX15 1524/4885 |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | CYP1A2 378/4885ALDH1A1 242/4885ALOX15 1354/4885 |
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | REN, PKD2, ALPI | CYP1A2 99/4885ALDH1A1 132/4885ALOX15 4471/4885 |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | CYP1A2 378/4885ALDH1A1 242/4885ALOX15 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.